MultiQure S.A. (WSE:MQR)
1.484
+0.006 (0.41%)
At close: Oct 27, 2026
MultiQure Company Description
MultiQure S.A., a biopharmaceutical company, researches and develops biological drugs and medical devices for therapeutic use.
Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin.
The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026.
The company was founded in 2013 and is based in Wroclaw, Poland.
MultiQure S.A.
| Country | Poland |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 7 |
| CEO | Filip Jelen |
Contact Details
Address: Szczytnicka 11 Wroclaw, 50-382 Poland | |
| Phone | 48 57 000 2829 |
| Website | multiqure.com |
Stock Details
| Ticker Symbol | MQR |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLPRBLG00010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Filip Jelen | Chief Executive Officer |